StockpollyBeta
Get App
Popularity #3,091
PEPG · NASDAQ · Biotechnology

PepGen (PEPG)

Develops peptide-enabled oligonucleotide therapies with a clinical focus on myotonic dystrophy type 1.

$2.79
vs last close−0.19 (−6.54%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000100
Gross profit000000000−100
252019302324312418191919
Research & development211614251819251813141313
455555665666
General & administrative405550665666
Other expenses000000000−100
Operating income−25−21−20−30−23−24−31−24−19−20−19−19
112221111111
Interest income212221111111
Other non-operating income0−1−2−2−2−1−1−1−11−1−1
Income before tax−23−19−18−28−21−23−30−23−18−18−18−18
Income tax expense00000−1000000
Net income from continuing operations−23−19−18−28−21−22−30−23−18−18−18−18
Other adjustments000000000000
Net income−23−19−18−28−21−22−30−23−18−18−18−18
EPS, basic−$0.98−$0.82−$0.63−$0.87−$0.66−$0.68−$0.92−$0.70−$0.55−$0.43−$0.26−$0.26
EPS, diluted−$0.98−$0.82−$0.63−$0.87−$0.66−$0.68−$0.92−$0.70−$0.55−$0.43−$0.26−$0.26
Weighted average shares, basic242429323333333333426969
Weighted average shares, diluted242429323333333333426969
EBITDA−25−19−18−26−20−22−29−22−18−19−17−14
Depreciation & amortization000210110104
EBIT−25−19−18−28−21−23−30−23−18−20−18−18